PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma

PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma

Diğer sürümleri göster (1)

Background: PIM serine/threonine kinases are often highly expressed in haematological malignancies. We have shown that PIM inhibitors reduced the survival and migration of leukaemic cells. Here, we investigated PIM kinases in diffuse large B-cell lymphoma (DLBCL) biopsy samples and DLBCL cell lines....

Detaylı Bibliyografya
Asıl Yazarlar:	Brault, L, Menter, T, Obermann, E, Knapp, S, Thommen, S, Schwaller, J, Tzankov, A
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	2012

Benzer Materyaller

PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
Yazar:: Brault, L, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Yazar:: Brault, L, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

STUDYING THE ROLE OF PIM KINASES IN FLT3-ITD-INDUCED LEUKEMIA REVEALED PIM1 AS REGULATOR OF CXCL12/CXCR4-MEDIATED HOMING AND MIGRATION
Yazar:: Brault, L, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Dissecting Proto-Oncogenic PIM Serine/Threonine Kinases in FLT3-ITD-Induced Leukemogenesis: PIM1 Regulates CXCL12/CXCR4-Mediated Homing and Migration
Yazar:: Gasser, C, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.
Yazar:: Grundler, R, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Structure and substrate specificity of the Pim-1 kinase
Yazar:: Bullock, A, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Structure and substrate specificity of the Pim-1 kinase.
Yazar:: Bullock, A, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
Yazar:: Pogacic, V, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
Yazar:: Bullock, A, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
Yazar:: Akué-Gédu, R, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Ruthenium half-sandwich complexes bound to protein kinase Pim-1
Yazar:: Debreczeni, J, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Ruthenium half-sandwich complexes bound to protein kinase Pim-1.
Yazar:: Debreczeni, J, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Electrostatically Enhanced Association of a Pim Kinase Substrate Revealed by Stochastic Detection
Yazar:: Harrington, L, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
Yazar:: Bataille, C, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1.
Yazar:: Ekambaram, R, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Stochastic detection of Pim protein kinases reveals electrostatically enhanced association of a peptide substrate.
Yazar:: Harrington, L, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics
Yazar:: Herbert, K, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
Yazar:: López-Ramos, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
Yazar:: López-Ramos, M, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Effect of single amino acid substitution observed in cancer on Pim-1 kinase thermodynamic stability and structure
Yazar:: Lori, C, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Crystal structure-guided design of bisubstrate inhibitors and photoluminiscent probes for protein kinases of the PIM family
Yazar:: Nonga, OE, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Bromodomains as therapeutic targets.
Yazar:: Muller, S, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Testis specific gene expression drives disease progression and Rituximab resistance in lymphoma.
Yazar:: Knapp, S
Baskı/Yayın Bilgisi: (2013)

Targeting kinases for the treatment of inflammatory diseases.
Yazar:: Müller, S, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents
Yazar:: Da Costa, D, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

INTRACELLULAR MARKERS OF DIFFERENTIATION IN BURKITTS-LYMPHOMA
Yazar:: Gallagher, C, ve diğerleri
Baskı/Yayın Bilgisi: (1984)

Therapeutic interventions for Burkitt lymphoma in children.
Yazar:: Okebe, J, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblas tic Leukaemia (ALL) Cells to DNA Damaging Agents
Yazar:: Da Costa, D, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
Yazar:: Bullock, A, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors.
Yazar:: Miduturu, C, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Identification of molecular factors mediating therapeutic resistance in diffuse large B-cell lymphoma (DLBCL)
Yazar:: Peng, Chenchen
Baskı/Yayın Bilgisi: (2024)

Identification of FOXP1 Transcriptional Targets in Diffuse Large B Cell Lymphoma
Yazar:: Camilleri, E, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Novel therapeutic approach for cutaneous T-Cell lymphoma
Yazar:: Low, Jian Hui
Baskı/Yayın Bilgisi: (2016)

Recently targeted kinases and their inhibitors-the path to clinical trials.
Yazar:: Knapp, S, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Recently targeted kinases and their inhibitors - the path to clinical trials
Yazar:: Knapp, S, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights (September, pg 3175, 2010)
Yazar:: Lopez-Ramos, M, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
Yazar:: Kizhakeyil, A, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Emerging intrinsic therapeutic targets for metastatic breast cancer
Yazar:: Li, Jiawei, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Diffuse large B-cell lymphoma
Yazar:: Gatter, K, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Elucidating Targetable Genetic Vulnerabilities in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Yazar:: Li, Audrey
Baskı/Yayın Bilgisi: (2024)